CRYO - American CryoStem Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
0.0900
-0.0100 (-10.00%)
As of 11:00AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1000
Open0.0900
Bid0.1050 x 5000
Ask1.5000 x 500
Day's Range0.0810 - 0.0900
52 Week Range0.0800 - 0.5500
Volume50,298
Avg. Volume22,273
Market Cap4.575M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    American CryoStem to Develop ATCELL(TM) Clinical Study for Duchene Muscular Dystrophy with RACEMD

    EATONTOWN, NJ / ACCESSWIRE / April 2, 2020 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products ...

  • ACCESSWIRE

    American CryoStem Corporation Issues Shareholder Letter

    During fiscal 2019, CRYO began transitioning its FDA registered laboratory facility from tissue bank status to full biologics manufacturer by upgrading our main laboratory facility in New Jersey. Additionally, the Company filed its first Investignational New Drug (IND) Application with the FDA, for its ATCELL™ adipose derived mesenchymal cellular therapy product, a major milestone for the Company and patients. As we enter 2020, our standardized stem cell processing platform provides all individuals with a cost effective "wellness" platform for their current or future regenerative medicine and/or cosmetic needs.

  • ACCESSWIRE

    American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND

    The Company and the Principal Investigator announce the addition of sub-investigators to the clinical trial team with extensive experience assessing and treating athletes and military personnel suffering ...

  • ACCESSWIRE

    American CryoStem Announces: FDA Accepted its Investigational New Drug Application for Post Concussion Syndrome

    EATONTOWN, NJ / ACCESSWIRE / September 18, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, announced today that it has submitted its first Investigational New Drug Application application for its ATCell™ product (the "Investigational Drug"), to the U.S. Food and Drug Administration (FDA). The FDA's acceptance for review of American CryoStem's IND application is a significant milestone for the Company and represents a meaningful step forward in the treatment of patients suffering from Post Concussion Syndrome ("PCS"), and for the advancement of Regenerative Medicine.

  • ACCESSWIRE

    American CryoStem Engages BioSolutions Clinical Research Center, LLC. and Principal Investigator for Chronic Concussive Syndrome IND

    EATONTOWN, NJ / ACCESSWIRE / September 11, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has contracted with BioSolutions Clinical Research Center, LLC. (“BioSolutions”) to conduct a clinical study (“Study”) of ATCELL™ (“Investigational Drug”) as part of a single center study under a protocol entitled: ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes during CRYOs Investigational New Drug (IND) filing with the FDA. BioSolutions located in La Mesa, CA.

  • ACCESSWIRE

    American CryoStem Engages IRB for IND Filling with the FDA

    The IRCM is a non-profit 501(c)(3) registered with the U.S. Department of Health and Human Services (HHS) and is qualified under the regulations to provide the required oversight. The FDA requires oversight of all IND clinical studies by an IRB.